C hina’s National Medical Products Administration (NMPA) has approved an investigational new drug (IND) application from Adcentrx Therapeutics to begin a Phase Ia/Ib study of ADRX-0706, a drug ...

Follows initiation of Phase 1a/1b study in the U.S.Company plans to include clinical centers in China to broaden geographic representation and accelerate patient enrollment into the Phase 1a/1b study ...

A new study details how a daily dose could prevent or delay the progression of the world’s third most common type of cancer.

Researchers from China Pharmaceutical University published data detailing the discovery and preclinical evaluation of novel tubulin polymerization inhibitors as potential anticancer agents. Discovery ...

Enzymes called DNA damage response kinases and tubulin acetyltransferase are the master regulators of the process, and promote the formation of the tubules. Enzymes deposit a chemical mark on a ...

Androgen deprivation is the mainstay of advanced prostate cancer treatment. Despite initial responses, almost all patients progress to castration-resistant prostate cancer (CRPC). The ...

During the past 20 years, the advent of neoadjuvant, primary, and adjuvant concurrent chemoradiotherapy has improved cancer care dramatically. Significant contributions have been made by ...